ACADIA Pharmaceuticals

Secular Trends And Pipeline Expansion Will Drive CNS Therapy Adoption

AnalystHighTarget

Not Invested

Community Contributor

Published

03 May 25

Updated

07 May 25

AnalystHighTarget's Fair Value

US$40.00

46.0% undervalued

10 Sep

US$21.59

46.6%

1.3%

46.6%

1.3%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

US$4046.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on07 May 25
Fair value Increased 2.56%

AnalystHighTarget Fair Value

US$40

46.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

10.33%

Biotech revenue growth rate

8.41%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.79%

Calculation

US$625.11m

Earnings '28

13.63x

PE Ratio '28

US$8.52b

Market Cap '28

US$8.52b

Market Cap '28

175.87m

No. shares '28

US$48.45

Share Price '28

US$48.45 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$39.80

Fair Value '25

Secular Trends And Pipeline Expansion Will Drive CNS Therapy Adoption

Shared on07 May 25Fair value Increased 2.56%

Shared on07 May 25
Fair value Increased 2.56%